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Abbreviation list  
COPD, chronic obstructive pulmonary disease; CRP, C-reactive protein; RCT, randomized 
controlled trials; CVD, cardiovascular disease; GOLD, the Global Initiative for Chronic Obstructive 
Lung Disease; FEV1, forced expiratory volume in 1 second; FEV1/FVC, a ratio of FEV1 to forced 
vital capacity; LDL-C, low-density lipoprotein cholesterol; RR, relative risk; CI: confidence interval; 
MD, mean difference. 
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Abstract 
Background: Much controversy persists regarding the place of statins in the treatment of patients 
with chronic obstructive pulmonary disease (COPD). This systematic review and meta-analysis 
sought to determine the clinical efficacy of statin therapy in COPD. 
Methods: We searched Medline, Embase, Cochrane databases, and Pubmed for relevant clinical 
studies. Randomized controlled trials comparing the effects of statins to placebo in COPD 
populations were included. Pooled estimates were calculated using a random-effects model. 
Heterogeneity was determined using the I2 statistic. 
Results: Ten trials with a total of 1471 patients were included. Statin treatment was associated with 
a larger improvement in exercise capacity, lung function, and St. George's Respiratory 
Questionnaire score compared with placebo, but there were no statistically significant differences in 
inflammatory markers, all-cause mortality, and safety outcomes; however, subgroup analysis 
indicated that statins improved clinical outcomes in the subjects from trials enrolling patients with 
overt cardiovascular disease, elevated baseline C-reactive protein, or high level of cholesterol. 
Conclusions: The findings from this systematic review suggest a role for statins in COPD patients 
with coexisting cardiovascular disease, evidence of increased systemic inflammation, or 
hyperlipidemia, in terms of improving exercise tolerance and pulmonary function. These findings 
need to be confirmed by randomized controlled trials specifically designed to test this hypothesis 
and identify appropriate patients for statin use. 
 
Keywords: COPD; statins; pulmonary; pooled analysis 
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Introduction 
Chronic obstructive pulmonary disease (COPD) is a progressive illness characterized by poorly 
reversible airflow limitation, lung function decline, and chronic inflammation. It is currently the fourth 
leading contributor of morbidity and mortality in the world, which results in increasing socioeconomic 
and individual disease burden1. There is no curative treatment for COPD, and existing medications 
have not been conclusively shown to reduce the progressive deterioration of lung function seen in 
many patients. Smoking cessation is a key intervention, but this doesn’t abolish disease 
progression1, 2. Effective therapy aiming for better management of COPD is urgently needed. 
  Statins are widely used for treating hypercholesterolemia. They function by inhibiting 
3-hydroxy-3-methylglutaryl coenzymeA reductase. In addition to their lipid lowering capacity, they 
also possess anti-inflammatory and immunomodulatory effects3. Recent research has shown that 
they may decrease airway inflammation, and reduce the level of systemic inflammatory marker such 
as C-reactive protein (CRP)4-5. With the accumulating evidence that COPD is both a 
pulmonary/airway and systemic inflammatory disease, the pleiotropic effects of statins may confer 
potential benefits in COPD patients6. Statins have been reported to reverse the progression of 
pulmonary emphysema and inhibit airway hyper-reactivity in rodent models7-8. Based on the findings, 
observational studies have been conducted which suggest  that statins had positive effects on 
reducing exacerbation rates and COPD related mortality9-10. By contrast, results from randomized 
clinical trials to test the efficacy of statins in a highly selected COPD population are much more 
controversial, suggesting little benefit3, 11.  
  This systematic review and meta-analysis was performed to evaluate the clinical impact of adding 
statin therapy compared to placebo in randomized controlled trials (RCTs) in COPD. In addition, we 
planned subgroup analysis based on inclusion vs. exclusion of patients with comorbid 
cardiovascular disease (CVD), high vs. low baseline CRP value, elevated vs. normal cholesterol 
level, and severity of COPD. We believe that this is the first such review. 
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Methods 
Search strategies 
This study was conducted and reported according to the Preferred Reporting Items for Systematic 
Reviews and Meta-Analyses guidelines (registered in the PROSPERO international prospective 
register of systematic reviews, CRD42017060594)12. Relevant articles were identified and selected 
by searching the databases: Medline (1966 to April 2017), Embase (1980 to April 2017), Cochrane 
controlled trials register (The Cochrane Library Issue 4, 2017), and PUBMED (updated to April 
2016). Detailed information of our search strategy is provided in the appendix 1. We examined 
bibliographies in relevant articles and conference proceedings. Internet-based sources of 
information on the results of clinical trials in statin and COPD were scanned for additional articles. 
There were no restrictions for language or publication date placed on the searches. Both full 
manuscripts and abstracts were considered. 
 
Inclusion and exclusion criteria 
Original studies were eligible for inclusion if they met the following criteria: (1) randomized, 
placebo-controlled; (2) evaluated the clinical efficiency of statin treatment in patients with COPD of 
any severity, defined according to the Global Initiative for Chronic Obstructive Lung Disease 
(GOLD) guideline; (3) had drop-out rate less than 20%; (4) provided data on at least one outcome 
of interest; (5) used a given patient population only once, if the same group appeared in other 
publications, only the most recent or complete report of a clinical trial was incorporated. 
 
Data extraction 
Two independent reviewers (WZ and YZ) separately screened the titles and abstracts, performed 
duplicate checking, and reviewed full articles that met the inclusion criteria. Data were 
independently abstracted from each identified reference with a predesigned review form, and 
disagreement was resolved by consensus. We retrieved study design and characteristics, patient 
clinical characteristics and demographics, intervention information, clinical outcomes, and 
duration of follow-up. The primary outcomes were exercise tolerance (6-minute walk distance) and 
lung function (forced expiratory volume in 1 second (FEV1) % of predicted value, FEV1 predicted; 
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a ratio of FEV1 to forced vital capacity, FEV1/FVC). Additional outcomes included CRP and 
pulmonary-related inflammatory markers (median neutrophil percentage in induced sputum), 
all-cause mortality, quality of life, acute exacerbations, drug discontinuation, low-density 
lipoprotein cholesterol (LDL-C), total cholesterol, and adverse events. 
 
Quality assessment 
We assessed the risk of bias of each fully published trial according to the Cochrane risk of bias 
tool. The main domains were checked, including random sequence generation, allocation 
concealment, blinding of participants, blinding of outcome assessment, attrition bias, selective 
reporting, and other bias. The judgments were expressed as “low risk”, “high risk”, or “unclear risk” 
of bias. Any disagreements were resolved by discussion and consensus. 
 
Statistical analysis 
Data analysis was performed using a random-effects model using Stata/SE 11.0 (StataCorp, 
College Station, TX). For all dichotomous data, the relative risk (RR) and 95% confidence intervals 
(CIs) were calculated for each independent study and for the summary statistic, with values of <1 
favoring statins. For studies reporting zero events in a treatment or control arm, we applied a 
half-integer continuity correction to calculate the relative risk (RR) and variance13. The mean 
difference (MD) and 95% CIs were calculated for continuous data. The RR or MD for each clinical 
event was considered to be significantly different if the P value was less than 0.05 (two sided). The 
magnitude of heterogeneity between trials was evaluated using the I2 statistic, with a value of 50% 
or more indicating a substantial level of heterogeneity. Publication bias was assessed using the 
Begg’s and Egger’s tests. 
  We performed subgroup analyses to address the clinical efficacy of statins in trials enrolling 
patients with concomitant CVD, evidence of systemic inflammation (raised CRP), elevated 
cholesterol level, or severe airflow limitation. Sensitivity analyses and meta-regression were 
conducted to examine the robustness of the findings and explore other important clinical 
differences among the studies. 
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Results 
Study description 
The study selection process is outlined in Figure 1. We identified 2921 citations. From them, twenty 
potentially eligible RCTs were identified4-5, 11, 14-30. Studies were excluded from the systematic review 
if they did not include COPD patients as the study population, did not have a completely randomized 
design, were commentaries and review articles, or were experimental reports in non-human species. 
Ultimately, 10 of the 20 studies were selected4-5, 11, 14-20; of those not included, three were excluded 
because they did not use a placebo control21-23, three because they used the same dataset as 
another study included in this meta-analysis24-26, one because it was a post-hoc analysis of a large 
statin-heart failure RCT27, one because one-quarter of the recruited patients did not complete the 
study28, one because most of the patients did not fulfil GOLD criteria for COPD29, and one because 
no outcomes of interest were reported30. All the included trials were published as peer-reviewed 
articles, and all of them were in English. Table 1 shows the baseline characteristics in each of the 
individual studies. 
 
Patients 
A total of 1471 COPD patients were recruited to these 10 trials; 728 were randomized to the statin 
group and 743 to the control group. Mean age ranged from 49 years to 72 years. Across the trials, 
the proportion of male subjects and current smokers ranged from 52% to 100% and 0% to 81%, 
respectively. Mean baseline FEV
 
% predicted ranged from 42% to 76%. Study duration ranged from 
1 to 12 months, with a mean follow-up of 4.4 months. Patients were permitted to take standard 
COPD medications including long-acting muscarinic antagonists, long-acting β2-agonists, inhaled 
corticosteroids, and use supplemental oxygen. Two studies were multicenter trials11, 20. All the trials 
recruited COPD patients without recent statin usage, except for one4. Four of the ten studies 
excluded participants with CVD4, 11, 15-16, and eight only enrolled stable COPD patients without a 
recent exacerbation4-5, 14-18, 20. Four types of statins were investigated in these trials: simvastatin, 
atorvastatin, rosuvastatin, and pravastatin. 
 
Trial quality 
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Methods of randomization and allocation concealment were adequately addressed in the majority of 
trials. Among the 10 included studies, nine were either double- or triple-blind, and the remaining one 
used a single-blind design5. All trials clearly stated withdrawal rates, which varied across trials and 
tended to be slightly lower in statin treatment group (4.4%) than in placebo group (5.2%). A 
summary of the “Risk of bias” assessment is presented in Figure 1S. 
 
Clinical outcomes 
Exercise capacity 
Figure 2 displays the change in 6-mintue walk distance, which was studied in five trials5, 14-16, 19. 
Overall there was a significant benefit in 6-mintue walk distance with statins; 6-minute walk distance 
was greater by 15.5 m (95% CI: 1.43 to 29.65 m; P=0.03). There was no observed heterogeneity 
between studies (I2=0%). 
 
Lung function 
Data for FEV1 were available in seven RCTs5, 11, 15, 17-20 (Figure 3). The Improvement in FEV1 % 
predicted was numerically but not significantly greater with statin therapy than with placebo (MD, 
3.2%; 95% CI: -0.30% to 6.78%; P=0.07). 
  Five studies evaluated the effect of statins on FEV1/FVC11, 17-20 (Figure 4). Statin usage was 
associated with a significant improvement in FEV1/FVC (MD, 2.7%; 95% CI: 0.05 to –5.25%; 
P=0.05). Tests of heterogeneity on all measures of spirometry were not significant (I2<5%). Taken 
together, our data suggested that statin therapy might improve the lung function by a small amount. 
 
Inflammatory status 
The effect of statins on CRP was determined in six studies4-5, 15-17, 20. There was a non-significant 
trend in CRP reduction in patients receiving statins compared with placebo (Figure 2S). There was 
a moderate degree of statistical heterogeneity among these six trials (I2=56.6%). 
  Three RCTs reported data on neutrophils percentage in sputum4-5, 16. There was no difference 
between statin and placebo groups (MD, -0.79%; 95% CI: -9.99% to 8.40%; P=0.87) (Figure 3S). 
Statistical heterogeneity was significant (I2=82.6%). 
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Quality of life 
The impact of statins on health-related life quality of COPD patient was evaluated using St George's 
Respiratory Questionnaire in three trials5, 11, 15 (Figure 5). There was a larger improvement with 
statin, as compared to placebo (MD, -8.9; 95% CI: -150 to -2.32; P=0.008). Between-trial 
heterogeneity was not obvious (I2=0%). 
 
All-cause mortality 
Four eligible trials that enrolled a total of 1054 patients reported all-cause mortality11, 14, 16, 19. There 
were 29 deaths among 518 individuals in the treatment groups and 31 deaths among 536 
individuals in the control groups. There was not statistically significant difference (RR, 0.97; 95% CI: 
0.60–1.58; P=0.91) (Figure 4S). There was no significant heterogeneity of findings across the 
studies (I2=0%). 
 
Drug safety 
As expected, statin therapy was associated with greatly reduced serum LDL-C and total cholesterol 
levels (data not shown), which confirmed a good compliance with statin usage study participants. 
Furthermore, withdrawal rate and the incidence of serious adverse events were both comparable 
between the statin and placebo groups (data not shown). 
 
Publication bias 
There was no obvious evidence for publication bias, as detected by the Begg’s and the Egger’s 
tests. 
 
Subgroup analysis 
Cardiovascular comorbidity 
Statins improved exercise tolerance in participants from the trials enrolling COPD patients with 
cardiovascular comorbidities, as evidenced by a significantly increased 6-minute walk distance (MD, 
19.1 m; 95% CI: 3.8 m to 34.4 m; P=0.01; I2=0%). In addition, there were trends towards better 
FEV1% predicted (MD, 3.75%; 95% CI: -0.08% to 7.58%; P=0.06; I2=0%) and FEV1/FVC (MD, 
2.74%; 95% CI: -0.31% to 5.78%; P=0.08; I2=20.4%), and lower CRP. By contrast, no benefits were 
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observed in patients from those studies that completely excluded patients with existing or potential 
CVD. 
 
Systemic inflammation 
We conducted a subgroup analysis according to baseline CRP levels, since the efficiency of statin 
on reducing inflammation has been shown to be related to baseline CRP17. In COPD patients with 
higher mean baseline CRP levels (baseline CRP value > 3 mg/L), the statin treated patients had a 
numerically better improvement in FEV1 % predicted (MD, 4.41%; 95% CI: -0.52% to 9.33%; P=0.08; 
I2=0%) and significantly better FEV1/FVC (MD, 5.00%; 95% CI: 1.02% to 8.98%; P=0.01); however 
this was not seen in patients with had lower baseline CRP levels. These observations were further 
strengthened by another subgroup analysis, based on the efficiency of statins in reducing systemic 
inflammation, which showed that they ameliorated the lung function parameters only in subjects 
from trials reporting decreased CRP levels after treatment. 
 
Cholesterol level 
A subgroup analysis was performed to test whether the benefits from statins were mediated through 
their lipid-lowering capacity. In studies conducted in the subjects with higher baseline LDL-C levels 
(baseline LDL-C value > 120 mg/dl), a significant benefit was seen for FEV1 predicted: MD, 3.82%; 
95% CI: -0.43% to 8.08%; P=0.08; I2=0%; FEV1/FVC: MD, 3.61%; 95% CI: 0.86% to 6.36%; P=0.01; 
I2=0%). This effect was not seen in studies conducted in patients with lower baseline LDL-C levels. 
 
Disease severity 
Baseline FEV1% predicted had no effect on the outcomes of statin treatment. 
 
Sensitivity analysis 
A sensitivity analysis was performed by using both random- and fixed-effect models, and practically 
the same outcomes were found, except the result of CRP, which significantly favored the statin 
group when using the fixed-effect model. Restricting our analysis to RCTs that only recruited stable 
COPD patients, or statin-naïve patients, or with longer observational period (more than 3 months) 
did not significantly alter the pooled results or any heterogeneity. 
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Meta-regression 
Meta-regression analysis found that patient number, statin class, methods of blinding 
(single/double/triple), or observational period had no significant effects on the major clinical 
outcomes. 
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Discussion 
In this systematic review and meta-analysis, pooled analysis of 10 RCTs to determine the efficacy of 
statins in treating patients with COPD generated some important observations. First, statins 
improved exercise tolerance, pulmonary function, and health-related life quality of COPD patients. 
Second, COPD patients with comorbid CVD, increased systemic inflammation, or hyperlipidaemia 
appeared to benefit more from statin therapy than the others of this population. Third, there was no 
association between statins and survival rate, although only a few trials in this analysis focused on 
this outcome and the mean study duration was short. 
  Other than being the first-line cholesterol-lowering medications for prevention of atherosclerotic 
CVD, statins have attracted growing interests for treating patients with COPD, with the underlying 
rationale related to their pleiotropic properties and the disease pathogenesis. The usefulness of 
various statins at different doses has been determined in both rat and mice models, which reported 
direct and protective effects on the broncho-pulmonary system31. Observational studies and a 
related systematic review support the conclusions from the animal researches, showing reduced 
morbidity and mortality in COPD patients receiving statins9, 32-34. By contrast, the largest prospective 
statin-COPD study (the STATCOPE trial) suggested that simvastatin did not reduce the 
exacerbation rate, and had no effect on lung function or health-related quality of life in patients with 
COPD11. These discordant results led to increasing controversy regarding the important but still 
unsolved puzzle: should patients with COPD be prescribed statins, unless they had identified lipid 
levels? 
  The current collective evidence suggests a role for statin therapy in several different aspects of 
COPD-specific outcomes. It also appears that patients with comorbid CVD and higher baseline 
lipids may have greater benefits including lung function benefits, whereas they had no effects in 
those with normal LDL-C level. These observations suggest COPD patients at elevated 
cardiovascular risk might be the appropriate subgroup for statin use. This finding accords with that 
suggested by Young et al in their STATCOPE critique, suggesting that statins maybe indicated in as 
many as 60-80% of COPD patients who have high cardiovascular risk and who have been 
historically under-treated with statin therapy, leading to poor outcomes in this ‘unhealthy non-user’ 
group3. This may explain the discrepancy between the result of our analysis and that of STATCOPE 
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trial, since in that study patients who met the indications for statin use based on their cardiovascular 
risk profiles were excluded. 
  COPD is increasingly recognized as a systemic disease that affects not only airway and lung, but 
also the cardiovascular system35-36. There appears to be a close relationship between COPD and an 
increased incidence of CVD37. A pooled analysis of two large epidemiologic researches recruiting 
more than 20,000 adults, reported that the prevalence of CVD in COPD patients was more than two 
times higher than in people without38. Furthermore, a substantially high cardiovascular mortality in 
patients with COPD has been observed, particularly in those with mild and moderate airflow 
limitataion39. In one of the largest COPD trials, cardiovascular events were responsible for 27% of 
the deaths, compared with 35% due to respiratory causes40. Since statins have been proven to 
reduce morbidity and mortality from CVD through inhibiting cholesterol biosynthesis, it is reasonable 
to assume that COPD patients with concomitant CVD or hyperlipemia would benefit from therapy 
with statins. 
  Unexpectedly, we found that statins appear to possess an ability to improve lung function in 
patients with COPD, which implies a direct benefit on statins on the pulmonary system. In support of 
this conclusion, previous studies identified a comparable decrease in mortality of COPD patients 
with both high and low cardiovascular risks, which also suggests a positive effect of statins outside 
of their cardiovascular-protective effects32. More interestingly, the sub-group analyses showed that 
statins appeared to exert their protective effect on pulmonary function only in patients with higher 
baseline CRP value. A plausible explanation for this phenomenon might be that statin-derived 
benefits may be primarily confined to COPD population with coexisting systemic inflammation. 
Previous research has reported a correlation between change in CRP, one of the most sensitive 
markers of inflammation, and improved clinical outcomes of COPD patients with statin use17. Our 
data suggest that since statins may downregulate inflammation only in patients with concomitant 
CVD or hyperlipemia, the inclusion of patients without these characteristics in studies may mask 
possible treatment effects. Exclusion of cardiovascular comorbidity that is normally associated with 
coexisting systemic inflammation, could have masked the potential pulmonary benefits of statins in 
the STATCOPE trial. Taken together, these observations lead to the hypothesis that the underlying 
mechanism of beneficial effects in COPD patients could be a result of inhibition of systemic 
inflammation by statins. 
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  Unlike the results of observational studies, we showed no effects of statin therapy on mortality in 
COPD patients1, 10, but the small patient cohorts in the RCTs were smal and the study periods were 
short, so the long-term effects of statins on life expectancy of COPD population remained unclear. 
  Whilst our findings suggested more prominent benefits from statin therapy in COPD patients with 
CVD, evidence of systemic inflammation, or hyperlipidaemia. It should be recognised that these 
three factors are commonly presented in COPD individuals, and are indications for statin use 
irrespective of the presence of COPD41. While this study demonstrated potential benefits of statins 
on lung function, a diagnosis of COPD is not, of itself, an indication for routine use of statins. Equally 
COPD is not a contraindication to statin treatment, so patients with COPD should be evaluated 
comprehensively for CVD and cardiovascular risks, in order to identify those warranting statin 
therapy. The data from this analysis suggests that, by identifying patients who meet current 
indications for statins, those with COPD might also benefit through their an effects on lung function 
and exercise capacity. 
 
Limitations 
This systematic review and meta-analysis has limitations. First, the overall study size of the 
contributing studies was small. Second,sSeveral important specific outcomes of COPD including 
acute exacerbations could not be analyzed, due to a lack of trials reporting such outcomes. Third, 
although this study highlighted a statin-induced benefit in trials recruiting participants with comorbid 
CVD, only some of them enrolled 100% of whom had both COPD and CVD. Future studies with 
rigorously predefined patient characteristics are warranted to better understand the potential 
benefits associated with statin use. Fourth, despite generally similar demographic characteristics 
and minimal evidence of heterogeneity among these RCTs, some confounding factors such as type 
of statin with different doses might have caused potential bias, and made it difficult to analyze the 
primary intervention of our interest. However, the inclusion of only randomized studies with a  
placebo controlled design and the use of random-effect model might be helpful to mitigate some of 
the possible study heterogeneities. Our attempts to investigate sources of heterogeneity through 
sensitivity analysis and meta-regression did not identify any factors significantly associated with 
treatment effect size. All these approaches support the robustness of this analysis, however, the 
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influences of unmeasured covariates cannot be completely ruled out. 
 
Conclusions 
The systematic review and meta-analysis showed that statins might improve exercise tolerance, 
lung function, and health-related quality of life in patients with COPD, particularly those with 
comorbid CVD, elevated systemic inflammation, or hyperlipidaemia. The findings support routine 
cardiovascular risk assessment in COPD population to identify patients who have a cardiovascular 
indication for statin treatment, since it might also bring direct benefits to pulmonary system. Finally, 
we feel that our observations justify a large RCT to test the hypotheses generated by this systematic 
review. 
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Figure legends 
Figure 1 Flow of study selection. 
Figure 2 Summary effects of statins versus placebo on changes in 6-minute walk distance. 
Figure 3 Summary effects of statins versus placebo on changes in FEV1% predicted. 
Figure 4 Summary effects of statins versus placebo on changes in FEV1/FVC. 
Figure 5 Summary effects of statins versus placebo on changes in SGRQ score. 
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Table 1 Characteristics of studies included in the analysis 
Study/Intervention Medication Dose Multicenter Blind Duration, month Patient number Age, y FEV1 Current smoker, n (%) Statin naive CVD excluded 
Chogtu 201614 Treatment rosuvastatin 10mg/day single double 3 32 61.4±8.4 - - Yes No 
Control placebo     30 65.9±9.7  -   
            
Criner 201411 Treatment simvastatin 40mg/day Multi double 12 433 62.2±8.5 41.6% 133 (30.7%) Yes Yes 
Control placebo     452 62.3±8.4  143 (31.6%)   
            
Ghobadi 201415 Treatment atorvastatin 40mg/day single double 2.1 25 47.3±7.5 76.3% 0 (0%) Yes Yes 
Control placebo     25 50.2±8.2  0 (0%)   
        
 
   
John 201516 Treatment simvastatin 20mg/day single double 1.5 33 64±7.3 53.9% 7 (21%) Yes Yes 
Control placebo     37 65±7.3  15 (41%)   
        
 
   
Lee 200817 Treatment pravastatin 40mg/day single double 6 62 70±8 53.5% 50 (81%) Yes No 
Control placebo     63 71±6  48 (76%)   
        
 
   
Lee 200918 Treatment pravastatin 40mg/day single double 6 32 71±8 56.6% 22 (81%) Yes No 
Control placebo     33 72±6  21 (81%)   
            
Maneechotesuwan4 2015 Treatment simvastatin 20mg/day single double 1 26 68.4±7.8 55.7% 5 (24%) No Yes 
Control placebo     26 68.4±7.8  5 (24%)   
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Moosavi 201319 Treatment atorvastatin 40mg/day single triple 6 24 65±11 43.8% - Yes No 
Control placebo     21 68±14  -   
        
 
   
Mroz 20155 Treatment atorvastatin 40mg/day single single 3 12 64.6±7.0 56.9% 5 (42%) Yes No 
Control placebo     6 68.4±6.5  2 (40%)   
        
 
   
Neukamm 201520 Treatment rosuvastatin 10mg/day Multi double 3 49 66±0.8 50.2% 12 (26%) Yes No 
Control placebo     50 63±1.0  23 (49%)   
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Online supplements are not copyedited prior to posting and the author(s) take full responsibility for the accuracy of all data.  
e-Appendix 1. Search strategies 
We searched Medline (1966 to April 2017), Embase (1980 to April 2017), Cochrane controlled trials 
register (The Cochrane Library Issue 4, 2017), and PUBMED (updated to April 2016) for eligible 
articles, using the terms: “chronic obstructive pulmonary disease”, “COPD”, “obstructive”, 
“bronchitis”, “airway obstruction”, “emphysema”, “mediastinal emphysema”, “subcutaneous 
emphysema”, “chronic obstructive lung disease”, “COLD”, “pulmonary heart disease”, “chronic 
pulmonary heart disease”, and “cor pulmonale”, combined with the following individual search 
terms: “hydroxy methylglutaryl coenzyme a reductase inhibitor”, “hydroxy methylglutaryl 
coenzyme a reductase”, “HMG-COA”, “HMG COA”, “statin”, “statins”, “simvastatin”, “lovastatin”, 
“mevastatin”, “pravastatin”, “atorvastatin”, “fluvastatin”, “rosuvastatin”, “cerivastatin”, and 
“pitavastatin”. Articles from these searches and relevant references cited therein were reviewed. 
Studies were included without any restrictions for language or publication date. 
 
 
 
e-Figure 1. Summary assessment of risk of bias. 
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e-Figure 2. Summary effects of statins versus placebo on changes in CRP. 
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Online supplements are not copyedited prior to posting and the author(s) take full responsibility for the accuracy of all data.  
e-Figure 3. Summary effects of statins versus placebo on changes in neutrophils percentage in 
sputum. 
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e-Figure 4. Summary effects of statins versus placebo on changes in all-cause mortality. 
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